1. Dapagliflozin targets SGLT2/SIRT1 signaling to attenuate the osteogenic transdifferentiation of vascular smooth muscle cells.
- Author
-
Li L, Liu H, Chai Q, Wei J, Qin Y, Yang J, Liu H, Qi J, Guo C, and Lu Z
- Subjects
- Animals, Humans, Mice, Male, Mice, Inbred C57BL, Cells, Cultured, Glucose metabolism, Glucosides pharmacology, Muscle, Smooth, Vascular metabolism, Muscle, Smooth, Vascular cytology, Muscle, Smooth, Vascular drug effects, Sirtuin 1 metabolism, Sirtuin 1 genetics, Cell Transdifferentiation drug effects, Benzhydryl Compounds pharmacology, Osteogenesis drug effects, Signal Transduction drug effects, Vascular Calcification metabolism, Vascular Calcification pathology, Vascular Calcification drug therapy, Sodium-Glucose Transporter 2 metabolism, Sodium-Glucose Transporter 2 genetics, Myocytes, Smooth Muscle metabolism, Myocytes, Smooth Muscle drug effects, Myocytes, Smooth Muscle cytology, Sodium-Glucose Transporter 2 Inhibitors pharmacology
- Abstract
Vascular calcification is a complication that is frequently encountered in patients affected by atherosclerosis, diabetes, and chronic kidney disease (CKD), and that is characterized by the osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs). At present, there remains a pressing lack of any effective therapies that can treat this condition. The sodium-glucose transporter 2 (SGLT2) inhibitor dapagliflozin (DAPA) has shown beneficial effects in cardiovascular disease. The role of this inhibitor in the context of vascular calcification, however, remains largely uncharacterized. Our findings revealed that DAPA treatment was sufficient to alleviate in vitro and in vivo osteogenic transdifferentiation and vascular calcification. Interestingly, our study demonstrated that DAPA exerts its anti-calcification effects on VSMCs by directly targeting SGLT2, with the overexpression of SGLT2 being sufficient to attenuate these beneficial effects. DAPA was also able to limit the glucose levels and NAD
+ /NADH ratio in calcified VSMCs, upregulating sirtuin 1 (SIRT1) in a caloric restriction (CR)-dependent manner. The SIRT1-specific siRNA and the SIRT1 inhibitor EX527 attenuated the anti-calcification effects of DAPA treatment. DAPA was also to drive SIRT1-mediated deacetylation and consequent degradation of hypoxia-inducible factor-1α (HIF-1α). The use of cobalt chloride and proteasome inhibitor MG132 to preserve HIF-1α stability mitigated the anti-calcification activity of DAPA. These analyses revealed that the DAPA/SGLT2/SIRT1 axis may therefore represent a viable novel approach to treating vascular calcification, offering new insights into how SGLT2 inhibitors may help prevent and treat vascular calcification., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF